7月A股震荡走强，结构性机会不断涌现，私募机构调研热情高涨，为后市布局积极"探路"。 第三方机构最新监测数据显示，7月共有657家私募证券管理人参与A股上市公司调研，覆盖358只个 股，合计调研1763次。从行业到个股，科技成长领域成为调研焦点。 7月私募调研呈现明显的头部集中效应。第三方机构私募排排网监测数据显示，7月52只个股获得不少于 10次调研，其中前十名个股（含并列排名，下同）均被调研至少24次。 电力设备龙头德福科技以74次调研领先，远超其他个股，该股在7月吸引了聚鸣投资、睿郡资产等众多 百亿私募扎堆关注。另一只电力设备股孚能科技以42次调研位居第二。通信行业的新易盛（34次）、汽 车行业的涛涛车业（32次）以及医药生物行业的海正药业（27次）进入前五。此外，农林牧渔、电子、 环保、机械设备等行业均有个股跻身前十。 | | 7月私募调研次数排名前十个股(含并列排名) | | | --- | --- | --- | | A 股简称 | 申万一级行业 | 被调研次数(次) | | 德福科技 | 电力设备 | 74 | | 孚能科技 | 电力设备 | 42 | | 新易盛 | 通信 | 34 | | 涛 ...

Group 1 - The average net value growth rate of active equity funds in the first seven months reached 12.01%, with many funds achieving over 100% performance [4][9] - The A-share market saw significant gains, with the North Exchange 50 index rising by 37.1%, and the majority of active equity funds reporting positive net value growth [3][4] - A total of 109 active equity funds had a net value growth rate exceeding 50%, with five funds surpassing 100%, indicating a strong recovery in the market [8][10] Group 2 - The top-performing fund, Changcheng Medical Industry Select A, achieved a return of 127.05%, followed by several other funds in the healthcare sector with returns above 100% [6][9] - The innovation drug sector has been a significant driver of performance, with funds focusing on this area seeing substantial gains [11][12] - The market outlook suggests that 2025 could be a breakout year for active equity funds, contingent on the continuation of favorable market conditions [10]

Core Viewpoint - The active equity funds have shown a strong performance in the first seven months of the year, with an average net value growth of 12.01%, and several funds achieving over 100% returns, indicating a resurgence in public equity funds [2][4][14]. Summary by Sections Market Performance - The A-share mainstream indices experienced an upward trend in the first seven months, with the North Securities 50 index rising by 37.1%, the highest among the indices [4]. - The overall performance of active equity funds significantly outperformed major indices, with an average net value growth rate of 11.65% for equity funds, compared to 6.61% for the Shanghai Composite Index [6][8]. Fund Performance - Active equity funds achieved an average net value growth rate of 12.01% in the first seven months, with ordinary stock funds and mixed equity funds showing even higher average growth rates of 15.07% and 14.7%, respectively [5][8]. - A total of 109 active equity funds reported net value growth rates exceeding 50%, with five funds surpassing 100%, and the top-performing fund achieving a remarkable 127.05% return [14][20]. Sector Highlights - The pharmaceutical sector dominated the performance rankings, with several funds focused on this sector achieving significant returns, such as the Changcheng Pharmaceutical Industry Selected A fund, which led with a 127.05% return [11][14]. - The innovation drug sector has been highlighted as a key area of growth, with funds like the Huatai-PB and other related products performing exceptionally well [18][20]. Index Fund Performance - Two index funds also achieved "double" performance, with the top performers being those tracking the innovative drug sector, reflecting the strong market interest in this area [17][19]. - The performance of index funds has been bolstered by the strong performance of the innovative drug sector, with several funds achieving net value growth rates exceeding 90% [18][19]. Future Outlook - The market is expected to continue its upward trajectory, with 2025 potentially being a significant year for active equity funds, driven by ongoing structural opportunities in sectors like innovative drugs and artificial intelligence [10][14][20].

新华财经上海8月1日电（林郑宏） 随着A股7月行情收官，当月A股涨幅榜也正式出炉。 得益于创新药板块的大幅上扬，排除7月上市的新股后，广生堂（300436.SZ）以218.94%的涨幅位居A股月内涨幅榜次席，仅次于"一月十倍"的现象级个股 上纬新材（688585.SH）。 连亏四年，股价飙升？ 广生堂全名为福建广生堂药业股份有限公司，于2015年4月22日在深交所上市。 中经社行业洞察产业服务数据平台（简称"行业洞察系统"）显示，广生堂是专注于肝病及抗病毒、抗感染治疗药物领域的国家重点高新技术企业，也是拥有 五大抗乙肝病毒临床用药的企业。公司坚持从传统仿制药企向创新药企转型的发展战略，持续引进和开发一类创新药和高端仿制药。公司下设多个子业务单 元，畅销品种十几款，涵盖肝病、男科、心血管、中成药等领域。 | 序号 | 发布日期 ◆ | 资质类别 | 资质名称 | 认定年度 ⇒ | | --- | --- | --- | --- | --- | | 1 | 2025-01-07 | 专精特新中小企业 | 省级专精特新中小企业 | 2025 | | 2 | 2024-12-30 | 高新技术企业 | 国家级高新技术 ...

另一方面，广东造纸业发布首个反内卷倡议书，行业密集涨价潮来袭，纸业股逆势走强；反内卷驱动提 价预期升温，物流股全天表现活跃，汽车股、黄金股、半导体股部分上涨。(格隆汇) 盘面上，大型科技股涨跌各异，其中，百度、阿里巴巴涨1%，美团、小米勉强翻红，快手跌3.12%，腾 讯跌近3%，网易跌1.47%，京东小幅下跌；大金融股(银行、保险、券商)、中字头等权重多数表现低 迷；连续上涨的生物医药股全线下跌，创新药概念股跌幅明显，同源康医药-B跌超14%，绿叶制药、三 生制药、信达生物、恒瑞医药、药明康德皆下跌；石油股走低，Q2业绩承压，预计上半年纯利下滑最 多43.7%，中国石油化工大跌近6%。 港股三大指数午后持续走低，8月首日迎来开门黑行情！市场近日来连续回调市场情绪表现低迷，截止 收盘，恒生指数跌1.07%，国企指数跌0.88%，二者均录得4连跌，恒生科技指数跌1.02%更是录得7连跌 行情。 ...

Core Viewpoint - The article discusses the recent fluctuations in the stock market, highlighting the significant drop in the South Korean stock market due to proposed tax increases, while also noting the strong performance of the photovoltaic sector in the Chinese market. Group 1: South Korean Stock Market - On August 1, the South Korean stock market experienced a sharp decline, with the Seoul Composite Index dropping nearly 4%, marking the largest drop since early April [6] - The decline was attributed to the government's plan to increase taxes on corporations and investors, including lowering the capital gains tax threshold and raising corporate tax rates [6][7] - Despite the drop, the index has risen over 30% this year, benefiting from optimistic sentiments surrounding corporate governance reforms [7] - The proposed tax increases have sparked strong backlash from retail investors, leading to a nationwide petition for withdrawal [7] - Samsung Electronics, the largest market cap stock, has seen consecutive declines due to disappointing earnings, raising concerns among foreign institutional investors [7] Group 2: Photovoltaic Sector Performance - In contrast to the overall market decline, the photovoltaic sector in the Chinese stock market saw significant gains, with the photovoltaic equipment sector rising by 2.4% [9] - Notable stocks included Jiejia Weichuang, which hit the daily limit with a 20% increase, and other companies like Haiyou New Materials and Shuangliang Energy also saw substantial gains [12] - The growth in the photovoltaic sector is supported by a recent notice from the Ministry of Industry and Information Technology regarding energy-saving inspections in the polysilicon industry, which is expected to enhance operational efficiency [15]

Market Overview - The market experienced a high and then a pullback, with the three major indices slightly down. The pharmaceutical sector continued its strong performance, with stocks like Qizheng Zangyao and Asia-Pacific Pharmaceutical hitting the daily limit. AI application stocks remained active, with companies like Qidi Design and Zhengzhong Design also reaching the limit. The photovoltaic sector saw a collective rebound, with stocks such as Jiejia Weichuang and Shuangliang Energy hitting the limit. Overall, more stocks rose than fell, with over 3,300 stocks in the Shanghai and Shenzhen markets showing gains, and today's trading volume was 1.62 trillion, a decrease of over 340 billion from the previous day [1]. Sector Highlights Pharmaceuticals - The pharmaceutical sector continued to surge, with Qizheng Zangyao achieving three consecutive limits, and Asia-Pacific Pharmaceutical and Fuyuan Pharmaceutical also hitting the limit. Notable stock performances include: - Qizheng Zangyao: Latest price 34.69, up 9.99%, market cap 18.389 billion [5] - Asia-Pacific Pharmaceutical: Latest price 7.40, up 9.96%, market cap 5.518 billion [6] - Fuyuan Pharmaceutical: Latest price 26.54, up 9.99%, market cap 12.739 billion [6] - Analysts believe the innovative drug sector's prosperity is sustainable, driven by policy support and increasing global competitiveness. The recovery of overseas orders and performance in the innovative drug supply chain is also noted, with expectations for a rebound in demand by 2025 [4][6]. Artificial Intelligence - The AI application sector saw significant gains, with stocks like Huanqiu Printing and Zhengzhong Design hitting the limit. Notable performances include: - Huanqiu Printing: Latest price 10.16, up 9.96%, market cap 3.252 billion [10] - Zhengzhong Design: Latest price 11.66, up 10.00%, market cap 3.301 billion [10] - Qidi Design: Latest price 16.08, up 20.00%, market cap 2.695 billion [10] - The recent strong debut of Figma on the NYSE, closing at $115.5 with a 250% increase, highlights the potential for AI-driven design tools to disrupt traditional markets [8][11]. Photovoltaics - The photovoltaic sector showed renewed strength, with stocks like Wenkai Co. and Jiejia Weichuang hitting the limit. Key stock performances include: - Wenkai Co.: Latest price 4.84, up 10.00%, market cap 2.145 billion [13] - Jiejia Weichuang: Latest price 66.19, up 20.00%, market cap 19.006 billion [12] - Jiejia Weichuang's recent earnings forecast indicates a net profit of 1.7 to 1.96 billion, representing a year-on-year growth of 38.65% to 59.85% [12]. - The Ministry of Industry and Information Technology's recent notice on energy conservation in the polysilicon industry is expected to accelerate supply-side reforms in the photovoltaic sector [12][14].

Investment Rating - The industry rating is "Positive" for the next 12 months, indicating an expected increase in performance relative to the CSI 300 index [5][61]. Core Insights - Recent collaboration between Heng Rui Medicine and GSK is expected to boost sentiment in the innovative drug sector, highlighting investment opportunities in pipeline realization, performance growth, and business collaborations [5][60]. - The 11th batch of centralized procurement is underway, suggesting a focus on pharmaceutical and medical device sectors that may benefit from optimized procurement rules [5][60]. - The report emphasizes the importance of monitoring performance reversals in related sectors, particularly in CXO companies, which have shown strong performance amid improving overseas demand and recovering orders [5][60]. Industry News - The Central Committee of the Communist Party and the State Council issued a plan for the implementation of a childcare subsidy system, which may impact the healthcare sector positively [14]. - The National Healthcare Security Administration released guidelines for the immediate settlement of basic medical insurance funds, aiming to enhance efficiency in fund disbursement [14]. Company Announcements - Heng Rui Medicine signed a collaboration and licensing agreement with GSK, which includes a $500 million upfront payment and potential milestone payments totaling approximately $12 billion for successful project developments [28]. - WuXi AppTec reported a 20.64% year-on-year increase in revenue for the first half of 2025, with net profit rising by 101.92% [29]. - CSPC Pharmaceutical announced an exclusive licensing agreement with Madrigal for the development of SYH2086, with potential total payments of up to $2.075 billion [30]. - Tigermed announced the acquisition of a stake in Japan's MICRON for approximately ¥484 million (about 23.48 million RMB) [31]. Market Review - For the week of July 25 to July 31, 2025, the Shanghai Composite Index fell by 0.90%, while the Shenzhen Component Index dropped by 1.64%. In contrast, the pharmaceutical and biological sector rose by 2.74%, with most sub-sectors showing positive performance [52]. - As of July 31, 2025, the price-to-earnings ratio (TTM) for the pharmaceutical and biological industry was 30.83, with a valuation premium of 161% compared to the CSI 300 index [57].

施罗德基金注意到，自2021年以来，中国居民的存款和贷款之间的差距不断拉大，这意味着巨大的居民 端资产配置需求。参考国内外及历史的情况，该机构认为优质股权或是一个很好的配置方向，估值有吸 引力的优质股票应成为很好的选择。 他认为，这个趋势可能在中长期持续。综合当前宏观环境和政策预期，流动性有望保持宽松水平，积极 的股市对于公众信心和消费有正面影响，且贸易关系的紧张态势也已经被充分预期，这些因素或有助于 缓解市场下行风险。 环球投资管理公司施罗德旗下施罗德基金称，4月初以来的中国内地和香港股市表现强势，随着关税对 经济的负面影响逐步减弱，巨大的中国居民端资产配置需求或将长期提振对优质股权的需求，积极的股 市对于公众信心和消费具有正面影响。 施罗德基金副总经理、首席投资官安昀指出，自美国特朗普政府在4月2日"解放日"宣布对等关税意向以 来，投资者开始关注全球经济增长，但是几个月以来的情况变化，使得金融市场对于关税的担忧总体上 是减弱的。 他表示，全球资本市场逐步好转，也在风险偏好和结构性行情上对于中国股市有所带动，以美国为主的 成熟资本市场过去数月的反弹对于全球其他区域的资本市场起到了带动的作用；特别是一些产业层 ...

Market Overview - The market experienced fluctuations with all three major indices slightly declining, with the Shanghai Composite Index leading the drop at 3559.95 points, down 0.37% [1] - Total trading volume in the Shanghai and Shenzhen markets was 1.60 trillion yuan, a decrease of 337.7 billion yuan compared to the previous trading day [1] Sector Performance - The pharmaceutical sector showed strong performance, with traditional Chinese medicine stocks seeing significant gains, such as Weikang Pharmaceutical hitting the daily limit [2] - Other sectors that performed well included AI applications and photovoltaic concepts, with notable stocks like Dingjie Zhizhi rising over 10% [2] Institutional Insights - According to Jufeng Investment Advisors, as the mid-year report disclosures peak, performance differentiation will become more pronounced, with profitable sectors attracting more capital [4] - Morgan Stanley Fund noted that the overall strong performance of the A-share market is attracting both domestic and foreign investors, with optimism building [4] - Anjue Asset highlighted the market's mixed sentiment, with increasing financing balances indicating investor confidence, while rapid sector rotations create confusion [5] Policy and Industry Developments - The Shanghai Municipal Communications Administration announced a plan to develop high-quality computing infrastructure, aiming to establish at least five large-scale computing centers by the end of 2025 [7] - In the context of competition in the delivery industry, major companies like Meituan and JD.com called for resisting disorderly competition to maintain market order [6] Company News - InnoSilicon's stock surged over 60% after being listed as a partner of NVIDIA, although the collaboration is still in the testing phase without substantial orders yet [7]